5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.08▼ | 1.07▼ | 1.07▼ | 1.06▼ | 1.09▼ |
MA10 | 1.07▼ | 1.06▼ | 1.07▼ | 1.07▼ | 1.13▼ |
MA20 | 1.06▼ | 1.07▼ | 1.07▼ | 1.10▼ | 1.21▼ |
MA50 | 1.08▼ | 1.08▼ | 1.09▼ | 1.15▼ | 1.25▼ |
MA100 | 1.10▼ | 1.10▼ | 1.11▼ | 1.22▼ | 5.69▼ |
MA200 | 1.11▼ | 1.14▼ | 1.17▼ | 1.21▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.002▲ | 0.002▲ | 0.002▲ | 0.000▼ | 0.016▲ |
RSI | 46.568▼ | 45.314▼ | 44.687▼ | 41.495▼ | 37.297▼ |
STOCH | 46.667 | 43.333 | 43.333 | 11.111▼ | 22.762 |
WILL %R | -80.000▼ | -80.000▼ | -80.000▼ | -100.000▼ | -90.244▼ |
CCI | -34.234 | 2.044 | -24.390 | -81.561 | -103.585▼ |
Monday, June 30, 2025 04:00 AM
MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron ...
|
Thursday, June 19, 2025 05:01 PM
MENLO PARK, Calif., May 29, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron ...
|
Sunday, June 01, 2025 05:00 PM
Eric Easom, the Chief Executive Officer of $ANTX, bought 10,000 shares of the company on 06-02-2025 for an estimated $10,665. This trade was reported by Quiver ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
03/07/25 | 1.05 | 1.11 | 1.05 | 1.05 | 66,614 |
02/07/25 | 1.05 | 1.1052 | 1.05 | 1.08 | 66,720 |
01/07/25 | 1.05 | 1.07 | 1.05 | 1.05 | 61,585 |
30/06/25 | 1.08 | 1.10 | 1.05 | 1.06 | 110,178 |
27/06/25 | 1.09 | 1.09 | 1.07 | 1.08 | 51,234 |
26/06/25 | 1.09 | 1.10 | 1.07 | 1.08 | 91,409 |
25/06/25 | 1.07 | 1.105 | 1.07 | 1.10 | 571,449 |
24/06/25 | 1.09 | 1.10 | 1.07 | 1.08 | 57,582 |
23/06/25 | 1.12 | 1.12 | 1.07 | 1.07 | 69,596 |
20/06/25 | 1.11 | 1.12 | 1.08 | 1.10 | 67,252 |
|
|
||||
|
|
||||
|
|